Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma
14th September 2021 – At IRBM we are passionate about helping companies develop medicines in a wide range of diseases and our scientists support the fundamental understanding of disease mechanisms. Science is about collaboration, and publication is an integral part of the scientific process. So, we are delighted to have out latest scientific paper published, produced in collaboration with several institutions including the University of Milan, and Milan’s Istituto Nazionale di Genetica Molecolare (INGM).
WHYUS
We offer a unique blend of broad scientific expertise, global pharma heritage, and unprecedented success in bringing drug discovery projects from conception to the clinic. With a passionate, interdisciplinary and accomplished team, and capabilities ranging from target validation to clinical candidate nomination, we bring great science to your project.
NewsEvents
Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer
Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma
IRBM & collaborators publish on techniques for characterizing peptides in Type 2 diabetes and a peptide drug discovery program for Huntington’s disease
On July 7 University and Research Minister Gaetano Manfredi visited IRBM
IRBMPHOTOS
